FDA will implement the SAS AI platform

2020: The conclusion of the transaction in the field of digital transformation

On January 14, 2021 it became known of what FDA will implement AI- the platform SAS to regulate the market of medicines USA. The transaction for the amount of 49.9 million dollars, on the one hand, became continuation of almost forty-year partnership, and with another – laid the foundation for the five-year agreement on complex purchase (BPA). Thus SAS will be directly involved in implementation of initiatives of FDA in the field of digital transformation.

FDA is an old client of SAS with big and experienced community of users and a set of crucial applications based on technologies of SAS. During this agreement there will take place large-scale implementation of the SAS Viya platform, the flagman cloud solution of the company opening access to the AI tools and machine learning. The first projects will be performed with the Center for assessment and a research of medicines (CDER) of FDA which helps to guarantee that the drugs intended for people are safe and effective.

Within projects business experts of SAS will reveal zones for upgrade in work of CDER and in other activities of FDA. Also in the period of partnership with the help of solutions of SAS it is planned:

• Promotion of an initiative of CDER of upgrade of programs of regulation of medicines.
• Ensuring supervision of production of drugs using analytics tools.
• Increase in efficiency of CDER.

The world enters an era of regulation of production of medicines. We are proud that FDA during this period selected technologies of SAS for such vital task as quality evaluation, efficiency and security of drugs from scales of the state again, – the founder and the CEO of SAS Jim Gudnayt comments.